Company intelligence / Profile preview

Enteris BioPharma

Boonton, New Jersey, United Statesmod3pharma.com ↗

Ownership: Public · SWKH
Employees: ~25
Development stage: Commercial

Overview

Ovarest® completed a Phase IIa trial with interim results reported. Tobrate™ received Fast Track and QIDP status from the FDA with Phase I safety completed. Multiple feasibility programs ongoing with pharma partners using proprietary oral peptide/small molecule delivery technologies.

Therapeutic areas: Women's HealthOncologyInfectious DiseasesNephrology
Modalities: PeptidesPeptidomimeticsSmall molecule
Industry: Biotech

Partnerships

Multiple undisclosed pharmaceutical partners for oral formulation development/licensingblue-chip pharma clients referenced but not named publiclyLicensee(s) for TBRIA™ osteoporosis product noted.

Financials

Market cap: $192.3M
Total revenue: $8M
Enterprise value: $181.7M

Beyond the preview

Go deeper on Enteris BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enteris BioPharma.

Explore the full profile